Evidence map›Paper›PMID 40461473›Full record

ArticleTranslational psychiatry2025

In vivo serotonin 1A receptor distribution in treatment-resistant depression.

Matej Murgaš, Christian Milz, Peter Stöhrmann, Jakob Unterholzner, Lukas Nics, Georg S Kranz, Andreas Hahn, Marcus Hacker, Siegfried Kasper, Rupert Lanzenberger and 1 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matej Murgaš *Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-7643-2182
Christian Milz *Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-1347-0744
Peter StöhrmannDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-7324-0414
Jakob UnterholznerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-9274-6990
Lukas NicsDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Georg S KranzDepartment of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.ORCID http://orcid.org/0000-0002-3892-1804
Andreas HahnDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-9727-7580
Marcus HackerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-4222-4083
Siegfried KasperDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-8278-191X
Rupert LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. rupert.lanzenberger@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-4641-9539
Godber M GodbersenDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. godber.godbersen@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-9739-0724

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/DOC33Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/KLI1006Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/KLI551Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) DI_2023-110Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation) 2014_A192Österreichischen Akademie der Wissenschaften (Austrian Academy of Sciences) DOC27221Vienna Science and Technology Fund (Wiener Wissenschafts-, Forschungs- und Technologiefonds) 10.47379/CS18039
6 · The paper itself

Abstract

Major depressive disorder (MDD) ranks among the leading causes of disability worldwide. An additional burden arises from treatment-resistance, defined by a lack of response to two or more adequate pharmacotherapeutic treatment trials. Unlike in MDD, where the serotonin 1A receptor subtype (5-HT

Indexed as

BrainDepressive Disorder, Treatment-ResistantMajor Depressive DisorderReceptor, Serotonin, 5-HT1AAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPiperazinesPositron-Emission TomographyPyridinesHTR1A protein, humanN-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamidePiperazinesPyridinesReceptor, Serotonin, 5-HT1A

Identifiers

PMID40461473
PMCPMC12134062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.